中国临床药理学杂志2016，Vol.32Issue(1)：24-26,3.DOI:10.13699/j.cnki.1001-6821.2016.01.008
长春瑞滨或吉西他滨联合顺铂治疗转移性三阴性乳腺癌的临床疗效与安全性评价
Clinical efficacy and safety of vinorelbine or gemcitabine combined with cisplatin in the treatment of metastatic triple-negative breast cancer
摘要
Abstract
Objective To evaluate the clinical efficacy and safety of vi-norelbine or gemcitabine combined with cisplatin for metastatic triple -negative breast cancer patients treated failure by anthracycline and ta-xane.Methods A total of 48 patients with metastatic triple -negative breast cancer treated failure by anthracycline and taxane were randomly divided into treatment group ( n =22 ) and control group ( n =26 ) . Treatment group was taken vinorelbine 25 mg· m-2 , day 1, 8 +cispla-tin 25 mg· m-2 , day 2-4.Control group was given gemcitabine 1000 mg· m-2 , day 1, 8 +cisplatin 25 mg· m-2 , day 2-4.The patients with bone metastasis received zoledronic acid (4 mg) treated after every 3-4 weeks when appropriate .The two regimens were 3 weeks as a cy-cle, and a total of six cycles were applied unless there was evidence of disease progression or intolerance of adverse reactions .The efficacy was evaluated every two cycles to compare the response rate , disease control rate and median time to progression ,and the rate of adverse reactions in the two groups.Results In the two groups , the objective response ratewas 45.45% and 46.15% respectively.The disease control rate was 77.27% and 80.77%.The median time to disease progression was 5.0 months and 5.2 months. The difference between the two groups was not significant ( P>0.05 ) .The main adverse reactions were bone marrow depression , gastrointestinal reaction and phlebitis , 1-2 grade in most cases , however , thrombocytopenia and rash in the control group were higher than those in the treatment group( P<0.05 ) , and the incidence of phlebitis in the treatment group was higher than that in the control group (P<0.05).Conclusion The short -term effect of vinorelbine or gemcitabine plus cisplatin in the treatment of anthracycline /taxane failure metastatic triple-negative breast cancer is similar and safe for clinical reference .关键词
转移性三阴性乳腺癌/长春瑞滨/吉西他滨/顺铂/化疗Key words
metastatic triple-negative breast cancer/vinorelbine/gemcitabine/cisplatin/chemotherapy分类
医药卫生引用本文复制引用
王俊斌,杨燕,汪子书,王明喜,郑荣生..长春瑞滨或吉西他滨联合顺铂治疗转移性三阴性乳腺癌的临床疗效与安全性评价[J].中国临床药理学杂志,2016,32(1):24-26,3.基金项目
安徽省高等学校自然科学研究基金资助项目(KJ2015B118by) （KJ2015B118by）
蚌埠医学院院级课题基金资助项目(Byky1373) （Byky1373）
